Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro

Dovitinib (TKI-258) is under development for the treatment of diverse cancer entities. No published information on its pharmacokinetic drug interaction potential is available. Thus, we assessed its interaction with important drug metabolising enzymes and drug transporters and its efficacy in multidr...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiss, Johanna, Theile, Dirk, Dvorak, Zdenek, Haefeli, Walter Emil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279137/
https://www.ncbi.nlm.nih.gov/pubmed/25521244
http://dx.doi.org/10.3390/pharmaceutics6040632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279137/
https://www.ncbi.nlm.nih.gov/pubmed/25521244
http://dx.doi.org/10.3390/pharmaceutics6040632

Ejemplares similares